# aTyr Pharma (ATYR) — Analyst Forecast

ATYR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/atyr/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Hold | 3 | 5 | 0 | 8 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| May 20, 2026 | Freedom Broker | Upgraded | Hold → Buy | $3.50 |
| Nov 7, 2025 | RBC Capital | Maintained | Sector Perform | $1.00 |
| Sep 16, 2025 | Wells Fargo | Downgraded | Overweight → Equal-Weight | $1.00 |
| Sep 16, 2025 | RBC Capital | Downgraded | Outperform → Sector Perform | $1.50 |
| Sep 15, 2025 | HC Wainwright & Co. | Downgraded | Buy → Neutral | — |
| Aug 22, 2025 | Jefferies | Maintained | Buy | $17.00 |
| Jun 20, 2025 | Wells Fargo | Maintained | Overweight | $25.00 |
| Jun 4, 2025 | HC Wainwright & Co. | Maintained | Buy | $35.00 |
| May 19, 2025 | HC Wainwright & Co. | Maintained | Buy | $35.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Maintained | Buy | $35.00 |
| Feb 18, 2025 | Leerink Partners | Initiated Coverage | Outperform | $16.00 |
| Jan 6, 2025 | Cantor Fitzgerald | Initiated Coverage | Overweight | — |
| Dec 10, 2024 | HC Wainwright & Co. | Maintained | Buy | $35.00 |
| Dec 3, 2024 | HC Wainwright & Co. | Maintained | Buy | $35.00 |
| Oct 29, 2024 | HC Wainwright & Co. | Maintained | Buy | $35.00 |
| Oct 4, 2024 | Wells Fargo | Initiated Coverage | Overweight | $17.00 |
| Sep 5, 2024 | Jefferies | Initiated Coverage | Buy | $9.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Maintained | Buy | $35.00 |
| Aug 14, 2024 | RBC Capital | Maintained | Outperform | $16.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Maintained | Buy | $35.00 |

## Frequently Asked Questions

### Is ATYR a buy, sell, or hold?

Analysts covering aTyr Pharma currently average a Hold rating: 3 buy, 5 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on ATYR?

On May 20, 2026, Freedom Broker upgraded aTyr Pharma to Buy with a price target of $3.50.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).